NasdaqGS:TECHLife Sciences
Bio-Techne (TECH): Evaluating Valuation After Cautious Management Outlook at Healthcare Conference
It is easy to see why Bio-Techne (TECH) has landed on investors’ radar this week. Management took the stage at the Baird Global Healthcare Conference and shared a cautious outlook for the business, pointing to ongoing market headwinds. While there was mention of double-digit growth in the pharma segment and in China, the tougher stance centered on major declines in the U.S. academic market and unpredictable demand in biotech, with funding still very tight. The frank tone from management...